Operating-Profit-Based Conditions for Exercising Stock Acquisition Rights
First written in FY2016-Q2. 12 of 31 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2020: 2 of 16 companies on the "Worse" side.
12 other companies' latest entry also says "Other".
- FY2026-H1Gain on cancellation of stock acquisition rights recognizedAnnual report
「Gain on cancellation of stock acquisition rights 3,351」
While no new stock option plans or other stock acquisition rights were issued, a gain on cancellation of stock acquisition rights of ¥3.351 million was recognized as extraordinary income. - FY2025Continued expiration of existing stock acquisition rights and recognition of gains on cancellationAnnual report
「Gain on cancellation of stock acquisition rights 40」
The 5th and 8th Stock Acquisition Rights expired, and a gain on cancellation of stock acquisition rights of ¥40 thousand was recognized during the fiscal year. The 2,240,500 13th Stock Acquisition Rights remained unconfirmed. - FY2025-H1Gain on cancellation of stock acquisition rights recognizedAnnual report
「Gain on cancellation of stock acquisition rights 40」
A gain on cancellation of stock acquisition rights of ¥40 thousand was recognized as extraordinary income during the interim accounting period. No new stock option plans or other stock acquisition rights were issued. - FY2024AdvancedAnnual report
「13th Stock Acquisition Rights (resolved by the Board of Directors on 13 September 2024)」
A total of 2,240,500 13th Stock Acquisition Rights were issued to 5 directors and 9 employees. The exercise period runs from 1 November 2025 to 18 October 2034, with graduated conditions under which the rights cannot be exercised if operating profit is below ¥300 million and 100% may be exercised at operating profit of ¥1.5 billion or more. - FY2024-Q2Continued recognition of gains on cancellation of stock acquisition rightsAnnual report
「Extraordinary income Gain on cancellation of stock acquisition rights 1,649」
While no new stock option plans or other stock acquisition rights were issued, a gain on cancellation of stock acquisition rights of ¥1.649 million was recognized as extraordinary income. - FY2024-Q1RestatedAnnual report
「① [Details of the stock option plan] Not applicable. ② [Status of other stock acquisition rights, etc.] Not applicable.」
No new stock option plans or other stock acquisition rights were issued during the quarter. - FY2023AdvancedAnnual report
「2022 11th Stock Acquisition Rights Expired 1,164,000 Unconfirmed balance － 2023 12th Stock Acquisition Rights Granted 1,853,600 Expired 62,100 Unconfirmed balance 1,791,500」
All 1,164,000 shares underlying the 11th Stock Acquisition Rights expired, while 1,791,500 of the 1,853,600 shares underlying the 12th Stock Acquisition Rights remained unconfirmed. A gain on cancellation of stock acquisition rights of ¥128.633 million arising from the expiration was also recognized. - FY2023-Q3Gain on cancellation of stock acquisition rights recognizedAnnual report
「Extraordinary income Gain on cancellation of stock acquisition rights 105,453」
While no new stock option plans or other stock acquisition rights were issued, a gain on cancellation of stock acquisition rights of ¥105.453 million was recognized as extraordinary income. - FY2023-Q2RestatedAnnual report
「The 12th Stock Acquisition Rights issued during the second quarter accounting period are as follows.」
The 1,853,600 12th Stock Acquisition Rights are restated as having been issued on 17 February 2023, with an exercise price of ¥290, an exercise period from 1 November 2023 to 17 February 2033, and graduated exercise conditions based on operating profit ranging from ¥300 million to ¥1.5 billion. - FY2023-Q1AdvancedAnnual report
「Allotment date (issue date) of stock acquisition rights 17 February 2023 Total number of stock acquisition rights 1,853,600 (1 share per stock acquisition right) Exercise period for stock acquisition rights 1 November 2023 to 17 February 2033 Operating profit below ¥300 million: No exercise permitted Operating profit of ¥300 million or more: 30% of the number allocated Operating profit of ¥500 million or more: 60% of the number allocated Operating profit of ¥800 million or more: 80% of the number allocated Operating profit of ¥1.2 billion or more: 90% of the number allocated Operating profit of ¥1.5 billion or more: 100% of the number allocated」
The Company disclosed the issue of a total of 1,853,600 Series 12 stock acquisition rights to 5 directors and 11 employees. The exercise period, annual exercise limit and staged exercise conditions from below ¥300 million to ¥1.5 billion or more in operating profit were specified. The Company also disclosed a resolution to cancel 1,024,000 of the 1,164,000 Series 11 stock acquisition rights in connection with the issue of the Series 12 rights, leaving 140,000 rights outstanding. - FY2022Expiry of existing stock acquisition rights and unfinalised balance of Series 11 stock acquisition rightsAnnual report
「2022 Series 11 stock acquisition rights Before vesting (shares) End of previous fiscal year — Granted 1,164,000 Expired — Vested — Unfinalised balance 1,164,000」
The 1,164,000 Series 11 stock acquisition rights remain unvested, while existing Series 1 through Series 10 stock acquisition rights continued to expire. A gain on cancellation of stock acquisition rights of ¥9,954 thousand was recognised during the fiscal year. - FY2022-Q2RestatedAnnual report
「Number of stock acquisition rights (units)* 1,164,000 Number of treasury stock acquisition rights (units)* — Class, description and number of shares underlying the stock acquisition rights (shares)* Common shares 1,164,000 (Note 2) Payment amount upon exercise of stock acquisition rights (¥)* 449 (Note 3) Exercise period for stock acquisition rights* From 1 November 2023 to 4 February 2032」
The Series 11 stock acquisition rights are reiterated as 1,164,000 rights with an exercise price of ¥449 and an exercise period from 1 November 2023 to 4 February 2032. The conditions that exercise is not permitted below operating profit of ¥1.5 billion and that up to 100% of the number allocated may be exercised at ¥3.0 billion or more are also stated. - FY2022-Q1AdvancedAnnual report
「Allotment date (issue date) of stock acquisition rights 4 February 2022 Total number of stock acquisition rights 1,164,000 (1 share per stock acquisition right) Exercise period for stock acquisition rights 1 November 2023 to 4 February 2032 Operating profit below ¥1.5 billion: No exercise permitted Operating profit of ¥3.0 billion or more: 100% of the number allocated」
The terms of the Series 11 stock acquisition rights approved in the previous fiscal year were finalised following completion of payment on 4 February 2022. The issue of 1,164,000 rights, the exercise period and the staged exercise conditions linked to operating profit were specified. - FY2021AdvancedAnnual report
「Total number of stock acquisition rights 1,164,000 (1 share per stock acquisition right) Exercise period for stock acquisition rights 1 November 2023 to 4 February 2032 Operating profit below ¥1.5 billion: No exercise permitted Operating profit of ¥1.5 billion or more: 50% of the number allocated Operating profit of ¥1.8 billion or more: 65% of the number allocated Operating profit of ¥2.1 billion or more: 80% of the number allocated Operating profit of ¥2.6 billion or more: 90% of the number allocated Operating profit of ¥3.0 billion or more: 100% of the number allocated」
The issue of 1,164,000 Series 11 stock acquisition rights approved on 14 January 2022, an exercise period from November 2023 to February 2032, and staged exercise conditions linked to operating profit levels from ¥1.5 billion to ¥3.0 billion were disclosed. - FY2021-Q3RestatedAnnual report
「① [Details of the stock option plan] Not applicable. ② [Status of other stock acquisition rights, etc.] Not applicable.」
The absence of disclosure of a new stock option plan or other stock acquisition rights has continued. - FY2021-Q2RestatedAnnual report
「① [Details of the stock option plan] Not applicable. ② [Status of other stock acquisition rights, etc.] Not applicable.」
The absence of disclosure of a new stock option plan or other stock acquisition rights has continued. - FY2021-Q1RestatedAnnual report
「① [Terms of the stock-option program] Not applicable. ② [Status of other share acquisition rights] Not applicable.」
There is no disclosure of a new stock option plan or other stock acquisition rights during the first quarter. - FY2020AdvancedAnnual report
「Other (exercise of stock acquisition rights) 4,600 85」
During the fiscal year, 4,600 shares decreased as a result of the exercise of stock acquisition rights, and total proceeds of ¥85 thousand from the disposal of treasury shares were recognised. Exercises of operating profit-linked stock acquisition rights have continued. - FY2020-Q3RestatedAnnual report
「① [Details of the stock option plan] Not applicable. ② [Status of other stock acquisition rights, etc.] Not applicable.」
This filing contains no disclosure of a new stock option plan or other stock acquisition rights. - FY2020-Q2RestatedAnnual report
「① [Details of the stock option plan] Not applicable. ② [Status of other stock acquisition rights, etc.] Not applicable.」
This filing contains no disclosure of a new stock option plan or other stock acquisition rights. - FY2020-Q1RestatedAnnual report
「① [Terms of the stock-option program] Not applicable. ② [Status of other share acquisition rights] Not applicable.」
This filing contains no disclosure of a new stock option plan or other stock acquisition rights. - FY2019AdvancedAnnual report
「The breakdown of the decrease in shares is as follows. Decrease due to the exercise of stock acquisition rights: 184,762 shares」
The report shows that 184,762 shares decreased during the fiscal year as a result of the exercise of stock acquisition rights, confirming that exercises of rights subject to conditions such as operating profit continued to progress. - FY2019-Q3RestatedAnnual report
「① [Terms of the stock-option program] Not applicable. ② [Status of other share acquisition rights] Not applicable.」
This filing contains no disclosure of a new stock option plan or other stock acquisition rights. It also contains no new changes, such as additional issuances, to the existing stock acquisition rights. - FY2018AdvancedAnnual report
「The breakdown of the decrease in shares is as follows. Decrease due to the exercise of stock acquisition rights: 86,340 shares」
The statement of changes in shareholders’ equity shows that rights covering 86,340 shares were exercised during the fiscal year in respect of existing stock acquisition rights. The exercise prices for each series were also adjusted due to the share split. - FY2018-Q3Exercise Price Adjustment Due to Stock SplitAnnual report
「Due to the share split, the exercise prices of stock acquisition rights exercised on or after 1 November 2018 will be adjusted as follows. Name | Exercise price before adjustment | Exercise price after adjustment Series 1 stock acquisition rights | ¥2,200 | ¥1,100 Series 5 stock acquisition rights | ¥2,623 | ¥1,312 Series 10 stock acquisition rights | ¥5,940 | ¥2,970」
Due to the share split, the exercise prices applicable on or after 1 November 2018 for the existing Series 1 through Series 10 stock acquisition rights will be adjusted. No new changes to the operating profit-linked exercise conditions themselves are disclosed. - FY2018-Q2RestatedAnnual report
「Exercise period for stock acquisition rights From 31 March 2019 To 30 March 2028 Operating profit below ¥2.5 billion: No exercise permitted Operating profit of ¥2.5 billion or more: 25% of the number allocated Operating profit of ¥2.7 billion or more: 40% of the number allocated Operating profit of ¥3.0 billion or more: 55% of the number allocated Operating profit of ¥3.4 billion or more: 70% of the number allocated Operating profit of ¥3.8 billion or more: 80% of the number allocated Operating profit of ¥4.0 billion or more: 100% of the number allocated」
The exercise period for Series 10 stock acquisition rights, from 31 March 2019 to 30 March 2028, and the staged exercise conditions from below ¥2.5 billion to ¥4.0 billion or more in operating profit are reiterated. - FY2018-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 13 March 2018, the Company resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, to issue the following stock acquisition rights to its directors and employees. Total number of stock acquisition rights: 238,750 (1 share per stock acquisition right). Exercise period: 31 March 2019 to 30 March 2028. Operating profit below ¥2.5 billion: No exercise permitted; operating profit of ¥2.5 billion or more: 25% of the number allocated; operating profit of ¥2.7 billion or more: 40%; operating profit of ¥3.0 billion or more: 55%; operating profit of ¥3.4 billion or more: 70%; operating profit of ¥3.8 billion or more: 80%; operating profit of ¥4.0 billion or more: 100%.」
The report describes the decision, based on the Board of Directors’ resolution dated 13 March 2018, to issue 238,750 paid stock options to 44 directors and employees. The exercise period, annual exercise limit and staged exercise conditions from below ¥2.5 billion to ¥4.0 billion or more in operating profit are specified. - FY2017RestatedAnnual report
「Operating profit below ¥2.0 billion: No exercise permitted Operating profit of ¥2.0 billion or more: 25% of the number allocated Operating profit of ¥2.2 billion or more: 40% of the number allocated Operating profit of ¥2.4 billion or more: 55% of the number allocated Operating profit of ¥2.6 billion or more: 70% of the number allocated Operating profit of ¥2.8 billion or more: 80% of the number allocated Operating profit of ¥3.0 billion or more: 100% of the number allocated」
The annual report confirms the mechanism for setting the exercisable percentage of Series 7 through Series 9 stock acquisition rights according to operating profit levels from below ¥2.0 billion to ¥3.0 billion or more. - FY2017-Q3AdvancedAnnual report
「The stock acquisition rights issued during the third quarter are as follows: 153,400 Series 7 stock acquisition rights, 370,500 Series 8 stock acquisition rights, and 277,200 Series 9 stock acquisition rights. The exercise period for each is from 20 July 2018 to 19 July 2027. Operating profit below ¥2.0 billion: No exercise permitted Operating profit of ¥2.0 billion or more: 25% of the number allocated Operating profit of ¥2.2 billion or more: 40% of the number allocated Operating profit of ¥2.4 billion or more: 55% of the number allocated Operating profit of ¥2.6 billion or more: 70% of the number allocated Operating profit of ¥2.8 billion or more: 80% of the number allocated Operating profit of ¥3.0 billion or more: 100% of the number allocated」
A total of 801,100 Series 7 through Series 9 stock acquisition rights were issued, with exercise periods, annual exercise limits and exercise percentages set according to operating profit levels. Different profit conditions were also established for each issuance, including a condition under which Series 8 rights could not be exercised below operating profit of ¥2.3 billion and could be exercised in full at ¥3.8 billion or more. - FY2016-Q3AdvancedAnnual report
「Finalisation of the terms of the issued stock acquisition rights (paid stock options) Based on resolutions of the Board of Directors dated 29 July 2016 and 5 August 2016, the previously undetermined terms of the stock acquisition rights issued for consideration to the Company’s employees were finalised on 26 August 2016, following completion of payment. Total number of stock acquisition rights 15,500 (1 share per stock acquisition right) Exercise period for stock acquisition rights 27 August 2017 to 26 August 2026 Operating profit below ¥1.8 billion: No exercise permitted Operating profit of ¥1.8 billion or more: 25% of the number allocated Operating profit of ¥2.0 billion or more: 40% of the number allocated Operating profit of ¥2.4 billion or more: 80% of the number allocated Operating profit of ¥2.7 billion or more: 90% of the number allocated Operating profit of ¥3.0 billion or more: 100% of the number allocated」
The terms of the issue of 15,500 paid stock options to 5 employees were finalised. The exercise period and the exercise percentages linked to operating profit were specified, with new conditions differing from those previously disclosed. - FY2016-Q2First statedAnnual report
「Exercise period for stock acquisition rights From 27 February 2017 To 26 February 2026 Operating profit below ¥1.5 billion: No exercise permitted Operating profit of ¥1.5 billion or more: 40% of the number allocated Operating profit of ¥1.8 billion or more: 55% of the number allocated Operating profit of ¥2.1 billion or more: 70% of the number allocated Operating profit of ¥2.4 billion or more: 80% of the number allocated Operating profit of ¥2.7 billion or more: 90% of the number allocated Operating profit of ¥3.0 billion or more: 100% of the number allocated」
An exercise period was set for the stock acquisition rights, with the exercisable percentage determined in stages according to operating profit levels from ¥1.5 billion to ¥3.0 billion or more.